GERN Insider Trading
GERON CORP | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at GERON CORP provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2010-06-04 03:35 | 2010-06-02 | EARP DAVID | Officer - SVP Bus Dev, Chief Patnt Couns | SELL | $5.43 | 10,617 | $57,650 | 203,298 | -5.0% |
| 2010-06-04 03:34 | 2010-06-02 | GREENWOOD DAVID | Officer - EVP and CFO | SELL | $5.43 | 14,746 | $80,071 | 259,998 | -5.4% |
| 2010-06-04 03:32 | 2010-06-02 | OKARMA THOMAS | Officer - President and CEO | SELL | $5.43 | 18,874 | $102,486 | 437,060 | -4.1% |
| 2010-05-26 03:34 | 2010-05-24 | Spink Katharine E. | Officer - VP Operations, Regen Med Progs | SELL | $5.11 | 385 | $1,967 | 99,757 | -0.4% |
| 2010-05-26 03:31 | 2010-05-24 | LEBKOWSKI JANE | Officer - SVP, CSO Regen Med | SELL | $5.11 | 2,336 | $11,937 | 207,508 | -1.1% |
| 2010-05-26 03:29 | 2010-05-24 | BEHRS MELISSA KELLY | Officer - SVP Oncology | SELL | $5.11 | 2,336 | $11,937 | 146,665 | -1.6% |
| 2010-05-26 03:26 | 2010-05-24 | EARP DAVID | Officer - SVP Bus Dev, Chief Patnt Couns | SELL | $5.11 | 2,336 | $11,937 | 213,915 | -1.1% |
| 2010-05-26 03:23 | 2010-05-24 | GREENWOOD DAVID | Officer - EVP and CFO | SELL | $5.11 | 3,503 | $17,900 | 274,744 | -1.3% |
| 2010-05-26 03:20 | 2010-05-24 | OKARMA THOMAS | Officer - President and CEO | SELL | $5.11 | 4,671 | $23,869 | 455,934 | -1.0% |
| 2010-05-01 00:22 | 2010-04-28 | Kelsey Stephen Michael | Officer - EVP, CMO, Oncology | SELL | $5.66 | 3,707 | $20,982 | 36,293 | -9.3% |
| 2009-06-02 04:26 | 2009-05-29 | Spink Katharine E. | Officer - VP Operations, Regen Med Progs | SELL | $6.35 | 400 | $2,540 | 10,142 | -3.8% |
| 2009-06-02 04:26 | 2009-05-29 | OKARMA THOMAS | Officer - President and CEO | SELL | $6.35 | 5,828 | $37,008 | 300,605 | -1.9% |
| 2009-06-02 04:25 | 2009-05-29 | LEBKOWSKI JANE | Officer - SVP, CSO Regen Med | SELL | $6.35 | 2,277 | $14,459 | 119,844 | -1.9% |
| 2009-06-02 04:25 | 2009-05-29 | BEHRS MELISSA KELLY | Officer - SVP Oncology | SELL | $6.35 | 2,277 | $14,459 | 59,001 | -3.7% |
| 2009-06-02 04:24 | 2009-05-29 | HARLEY CALVIN | Officer - VP, CSO Telomerase Tech | SELL | $6.35 | 2,277 | $14,459 | 69,036 | -3.2% |
| 2009-06-02 04:24 | 2009-05-29 | EARP DAVID | Officer - SVP Bus Dev, Chief Patnt Couns | SELL | $6.35 | 2,277 | $14,459 | 126,251 | -1.8% |
| 2009-06-02 04:23 | 2009-05-29 | GREENWOOD DAVID | Officer - EVP and CFO | SELL | $6.35 | 3,416 | $21,692 | 153,247 | -2.2% |
| 2009-06-02 04:22 | 2009-05-29 | Benedetti Fabio M | Officer - SVP, Chief Med Off, Oncology | SELL | $6.35 | 2,277 | $14,459 | 38,060 | -5.6% |
| 2009-05-29 03:39 | 2009-05-26 | Spink Katharine E. | Officer - VP Operations, Regen Med Progs | SELL | $6.75 | 2,864 | $19,332 | 10,542 | -21.4% |
| 2009-05-29 03:39 | 2009-05-26 | OKARMA THOMAS | Officer - President and CEO | SELL | $6.75 | 46,669 | $315,016 | 306,433 | -13.2% |
| 2009-05-29 03:38 | 2009-05-26 | BEHRS MELISSA KELLY | Officer - SVP Oncology | SELL | $6.75 | 6,819 | $46,028 | 61,278 | -10.0% |
| 2009-05-29 03:38 | 2009-05-26 | LEBKOWSKI JANE | Officer - SVP, CSO Regen Med | SELL | $6.75 | 14,092 | $95,121 | 122,121 | -10.3% |
| 2009-05-29 03:37 | 2009-05-26 | HARLEY CALVIN | Officer - VP, CSO Telomerase Tech | SELL | $6.75 | 10,001 | $67,507 | 71,313 | -12.3% |
| 2009-05-29 03:36 | 2009-05-26 | GREENWOOD DAVID | Officer - EVP and CFO | SELL | $6.75 | 19,320 | $130,410 | 156,663 | -11.0% |
| 2009-05-29 03:34 | 2009-05-26 | EARP DAVID | Officer - SVP Bus Dev, Chief Patnt Couns | SELL | $6.75 | 15,456 | $104,328 | 128,528 | -10.7% |
| 2009-04-07 04:24 | 2009-04-03 | Benedetti Fabio M | Officer - SVP, Chief Med Off, Oncology | SELL | $4.44 | 5,195 | $23,066 | 40,337 | -11.4% |
| 2009-02-04 04:05 | 2009-02-02 | BEHRS MELISSA KELLY | Officer - SVP Oncology | SELL | $8.12 | 14,765 | $119,892 | 0 | -100.0% |
| 2009-01-31 05:12 | 2009-01-30 | WALKER JOHN PETER | Director | OPT+S | $8.28 | 48,617 | $402,549 | 39,119 | 0.0% |
| 2009-01-31 05:11 | 2009-01-29 | HARLEY CALVIN | Officer - VP and CSO | SELL | $7.09 | 30,489 | $216,191 | 99,157 | -23.5% |
| 2009-01-07 03:22 | 2009-01-05 | OKARMA THOMAS | Officer - President and CEO | SELL | $4.90 | 12,512 | $61,309 | 353,102 | -3.4% |
| 2009-01-07 03:22 | 2009-01-05 | LEBKOWSKI JANE | Officer - SVP Regen Medicine | SELL | $4.90 | 8,861 | $43,419 | 149,906 | -5.6% |
| 2009-01-07 03:22 | 2009-01-05 | BEHRS MELISSA KELLY | Officer - SVP Oncology | SELL | $4.90 | 8,861 | $43,419 | 79,877 | -10.0% |
| 2009-01-07 03:21 | 2009-01-05 | HARLEY CALVIN | Officer - VP and CSO | SELL | $4.90 | 8,861 | $43,419 | 125,698 | -6.6% |
| 2009-01-07 03:21 | 2009-01-05 | GREENWOOD DAVID | Officer - EVP and CFO | SELL | $4.90 | 10,732 | $52,587 | 179,560 | -5.6% |
| 2009-01-07 03:21 | 2009-01-05 | EARP DAVID | Officer - SVP Bus Dev, Chief Patnt Couns | SELL | $4.90 | 8,861 | $43,419 | 155,764 | -5.4% |
| 2008-11-06 04:20 | 2008-11-05 | BEHRS MELISSA KELLY | Officer - SVP Oncology | SELL | $4.05 | 23,845 | $96,572 | 88,738 | -21.2% |
| 2008-01-05 05:00 | 2008-01-04 | OKARMA THOMAS | Officer - President and CEO | SELL | $5.34 | 13,166 | $70,306 | 361,492 | -3.5% |
| 2008-01-05 04:59 | 2008-01-04 | LEBKOWSKI JANE | Officer - SVP Regen Medicine | SELL | $5.34 | 8,911 | $47,585 | 147,619 | -5.7% |
| 2008-01-05 04:58 | 2008-01-04 | BEHRS MELISSA KELLY | Officer - SVP Oncology | SELL | $5.34 | 8,911 | $47,585 | 94,285 | -8.6% |
| 2008-01-05 04:56 | 2008-01-04 | HARLEY CALVIN | Officer - VP and CSO | SELL | $5.34 | 8,911 | $47,585 | 119,389 | -6.9% |
| 2008-01-05 04:55 | 2008-01-04 | GREENWOOD DAVID | Officer - EVP and CFO | SELL | $5.34 | 11,039 | $58,948 | 171,783 | -6.0% |
| 2008-01-05 04:53 | 2008-01-04 | EARP DAVID | Officer - SVP Bus Dev, Chief Patnt Couns | SELL | $5.34 | 8,911 | $47,585 | 154,818 | -5.4% |
| 2007-11-14 03:57 | 2007-11-12 | GREENWOOD DAVID | Officer - EVP and CFO | SELL | $7.20 | 4,000 | $28,800 | 179,245 | -2.2% |
| 2007-05-22 04:08 | 2007-05-18 | HARLEY CALVIN | Officer - VP and CSO | OPT+S | $9.19 | 30,000 | $275,610 | 57,223 | 0.0% |
| 2006-01-11 03:29 | 2006-01-09 | BEHRS MELISSA KELLY | Officer - VP, Oncology | SELL | $8.56 | 8,441 | $72,255 | 7,363 | -53.4% |
| 2006-01-11 03:28 | 2006-01-09 | LEBKOWSKI JANE | Officer - SVP, Regenerative Medicine | SELL | $8.56 | 10,676 | $91,387 | 19,254 | -35.7% |
| 2006-01-11 03:28 | 2006-01-09 | OKARMA THOMAS | Director, Officer - President and CEO | SELL | $8.56 | 12,320 | $105,459 | 31,575 | -28.1% |
| 2006-01-11 03:27 | 2006-01-09 | HARLEY CALVIN | Officer - Chief Scientific Officer | SELL | $8.56 | 9,183 | $78,606 | 8,035 | -53.3% |
| 2006-01-11 03:15 | 2006-01-09 | GREENWOOD DAVID | Officer - Executive VP and CFO | SELL | $8.56 | 12,183 | $104,286 | 16,977 | -41.8% |
| 2006-01-11 03:14 | 2006-01-09 | EARP DAVID | Officer - SVP Bus Dev / Chf Patent Couns | SELL | $8.56 | 11,323 | $96,925 | 20,396 | -35.7% |
How to Interpret $GERN Trades
Not every insider transaction in GERON CORP is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $GERN shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for GERN
Insider activity data for GERON CORP is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $GERN, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.